Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
eTheRNA immunotherapies NV
eTheRNA immunotherapies NV
Activities:
Pharmaceutical
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint
Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
Memel Biotech and Therabest collaborate to develop exosome-based cell therapies
The partnership will aim to develop, manufacture and distribute novel exosome cell therapies in a range of therapeutic areas
Ipsen and Skyhawk Therapeutics partner to develop RNA-targeting drug candidates
The USD $1.8bn deal will support the development of novel RNA-modulating drugs using Skyhawk's proprietary technology
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Manufacturing
etherna appoints Shelly West as Business Development Director, US
Shelly arrives from Cellpoint Biosciences and will be in charge of expanding etherna's US customer base
Ingredients
LNP formulation improves mRNA vaccine efficacy and tolerability
S-Ac7-DOG encapsulated mRNA demonstrated markedly higher transfection, lower reactogenicity, and higher accumulation in the vaccine draining lymph nodes
Research & Development
Almirall and etherna to develop mRNA-based therapies in medical dermatology
The collaboration leverages etherna’s proprietary mRNA and lipid nanoparticle (LNP) technology with Almirall’s expertise in the dermatology space
Manufacturing
eTheRNA Manufacturing announces LNP development service
The service uses the company’s proprietary lipid libraries and proprietary formulations to facilitate targeted delivery and tailored biodistribution solutions
Research & Development
eTheRNA announces mRNA research agreement with Merck
The ongoing pandemic has underlined the capability for mRNA vaccines as a therapeutic modality
Finance
eTheRNA immunotherapies opens Hong Kong office
The subsidiary will support and build on the company’s growing activities in China and broader Asia-Pacific
Research & Development
New eTheRNA led international consortium to develop COV-2 mRNA vaccineCV-19
eTheRNA launches an international consortium and starts development of cross-strain protective CoV-2 mRNA vaccine for high risk populations
Subscribe now